Nivolumab
Vulvar Neoplasms
Instituto do Cancer do Estado de São Paulomonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Vulvar Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Star0602 Marengo Therapeutics, Inc. | Phase 1/2 | CCC |
Ganciclovir Gene Surgery LLC | Phase 1 | CC |
Stimotimagene Copolymerplasmid Gene Surgery LLC | Phase 1 | CC |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →